Biodesix Raises $8.8M More
Boulder-based Biodesix, a developer of diagnostic tests for the personalized medicine market, has raised $8.8M in a follow-on sale of its Series D preferred shares, the firm announced. The firm said the funding came from its existing investors. Names of those investors were not announced. Biodesix said it will use the funds for ongoing development of its technology platform, plus sales and marketing. Biodesix is developing diagnostic tests for a number of conditions; the firm said its first product is a serum protein test for guiding the treatment of patients with advanced non-small cell lung cancer (NSCLC).
posted on Friday, April 12, 2013 (Link to more information)
Related companies:
BIODESIX INC
Related stories:
> Biodesix Raises $12M More In Series E Funding
> Biodesix Brings Series E To $14.4M
> Biodesix Finds $8.3M In Series E Funding
> Biodesix Scores $7.1M For Lung Cancer Tests
> Tendril Raises $15.2M In Funding Round
Techrockies.com Home